酪氨酸激酶抑制剂对慢性髓细胞性白血病儿童生长发育影响的研究进展  

Progress on the effects of tyrosine kinase inhibitors on the growth and development of children with chronic myelogenous leukemia

作　　者：汪星辰 杨文钰 Wang Xingchen;Yang Wenyu(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所)、实验血液学国家重点实验室、国家血液系统疾病临床医学研究中心、细胞生态海河实验室,天津300020 [2]天津医学健康研究院,301600

出　　处：《国际儿科学杂志》2024年第8期548-552,共5页International Journal of Pediatrics

基　　金：中国医学科学院医学与健康科技创新工程重大协同创新项目(2021-I2M-1-003)。

摘　　要：酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)的应用改变了儿童慢性髓细胞性白血病(chronic myeloid leukemia,CML)的治疗模式,显著改善了患儿预后。然而,长期使用TKI治疗CML患儿可能伴随的潜在不良反应值得关注,目前国内外均有研究发现应用TKI会使CML患儿的生长发育减速。该文对TKI导致CML患儿生长障碍的机制、临床研究结果、改善方法以及治疗过程中监测指标的研究进展进行综述。The introduction of tyrosine kinase inhibitor(TKI)into the treatment of pediatric chronic myelogenous leukemia(CML)has led to treatment mode changes and significant improvements in prognosis.However,the potential adverse effects associated with long-term TKI therapy in pediatric CML patients merit close attention.Recent domestic and international studies have noted that TKI therapy may impede growth and development in children.This article reviews the research progress on the mechanism,clinical research findings,improvement methods,and monitoring indicators of growth disorder in children with CML caused by TKI.

关 键 词：儿童 酪氨酸激酶抑制剂 慢性髓细胞性白血病 生长发育 

分 类 号：R733.72[医药卫生—肿瘤]